Document:

Document

Exhibit 10.1

EMCORE CORPORATION
AMENDED AND RESTATED 2019 EQUITY INCENTIVE PLAN

1.    PURPOSE OF PLAN
The purpose of this EMCORE Corporation Amended and Restated 2019 Equity Incentive Plan (this “Plan”) of EMCORE Corporation, a New Jersey corporation (the “Corporation”), is to promote the success of the Corporation by providing an additional means through the grant of awards to attract, motivate, retain and reward selected employees and other eligible persons and to enhance the alignment of the interests of the selected participants with the interests of the Corporation’s stockholders. 
2.    ELIGIBILITY
The Administrator (as such term is defined in Section 3.1) may grant awards under this Plan only to those persons that the Administrator determines to be Eligible Persons.  An “Eligible Person” is any person who is either: (a) an officer (whether or not a director) or employee of the Corporation or one of its Subsidiaries; (b) a director of the Corporation or one of its Subsidiaries; or (c) an individual consultant or advisor who renders or has rendered bona fide services (other than services in connection with the offering or sale of securities of the Corporation or one of its Subsidiaries in a capital-raising transaction or as a market maker or promoter of securities of the Corporation or one of its Subsidiaries) to the Corporation or one of its Subsidiaries and who is selected to participate in this Plan by the Administrator; provided, however, that a person who is otherwise an Eligible Person under clause (c) above may participate in this Plan only if such participation would not adversely affect either the Corporation’s eligibility to use Form S-8 to register under the Securities Act of 1933, as amended (the “Securities Act”), the offering and sale of shares issuable under this Plan by the Corporation or the Corporation’s compliance with any other applicable laws.  An Eligible Person who has been granted an award (a “participant”) may, if otherwise eligible, be granted additional awards if the Administrator shall so determine.  As used herein, “Subsidiary” means any corporation or other entity a majority of whose outstanding voting stock or voting power is beneficially owned directly or indirectly by the Corporation; and “Board” means the Board of Directors of the Corporation.
3.    PLAN ADMINISTRATION
3.1    The Administrator.  This Plan shall be administered by and all awards under this Plan shall be authorized by the Administrator.  The “Administrator” means the Board or one or more committees (or subcommittees, as the case may be) appointed by the Board or another committee (within its delegated authority) to administer all or certain aspects of this Plan.  Any such committee shall be comprised solely of one or more directors or such number of directors as may be required under applicable law.  A committee may delegate some or all of its authority to another committee so constituted, subject to the provisions of this Plan and any other policies as the Corporation, the Board or such committee may adopt.  The Board or a committee comprised solely of directors may also delegate, to the extent permitted by N.J.S.A. Section 14A:8-1(4) (or successor provision) and any other applicable law, to one or more officers of the Corporation, its authority under this Plan.  The Board or another committee (within its delegated authority) may delegate different levels of authority to different committees or persons with administrative and grant authority under this Plan.  Unless otherwise provided in the Bylaws of the Corporation or the applicable charter of any Administrator: (a) a majority of the members of the acting Administrator shall constitute a quorum, and (b) the vote of a majority of the members present assuming the presence of a quorum or the unanimous written consent of the members of the Administrator shall constitute action by the acting Administrator.
3.2    Powers of the Administrator.  Subject to the express provisions of this Plan, the Administrator is authorized and empowered to do all things necessary or desirable in connection with the authorization of awards and the administration of this Plan (in the case of a committee or delegation to one or more officers, within any express limits on the authority delegated to that committee or person(s)), including, without limitation, the authority to:
(a)    determine eligibility and, from among those persons determined to be eligible, determine the particular Eligible Persons who will receive an award under this Plan;
(b)    grant awards to Eligible Persons, determine the price (if any) at which securities will be offered or awarded and the number of securities to be offered or awarded to any of such persons (in the case of securities-based awards), determine the other specific terms and conditions of awards consistent with the express limits of this Plan, establish the installment(s) (if any) in which such awards shall become exercisable or shall vest (which may include, without limitation, performance and/or time-based schedules), or determine that no delayed exercisability or vesting is required, establish any applicable performance-based exercisability or vesting requirements, determine the circumstances in which any performance-based goals (or the applicable measure of performance) will be adjusted and the nature and impact of any such adjustment, determine the extent (if any) to which any applicable exercise and vesting requirements have been satisfied, establish the events (if any) on which exercisability or vesting may accelerate (which may include, without limitation, retirement and other specified terminations of employment or services, or other circumstances), and establish the events (if any) of termination, expiration or reversion of such awards;

Exhibit 10.1

(c)    approve the forms of any award agreements (which need not be identical either as to type of award or among participants);
(d)    construe and interpret this Plan and any agreements defining the rights and obligations of the Corporation, its Subsidiaries, and participants under this Plan, make any and all determinations under this Plan and any such agreements, further define the terms used in this Plan, and prescribe, amend and rescind rules and regulations relating to the administration of this Plan or the awards granted under this Plan;
(e)    cancel, modify, or waive the Corporation’s rights with respect to, or modify, discontinue, suspend, or terminate any or all outstanding awards, subject to any required consent under Section 8.6.5;
(f)    accelerate, waive or extend the vesting or exercisability, or modify or extend the term of, any or all such outstanding awards (in the case of options or stock appreciation rights, within the maximum term of such awards) in such circumstances as the Administrator may deem appropriate (including, without limitation, in connection with a retirement or other termination of employment or services, or other circumstances) subject to any required consent under Section 8.6.5;
(g)    adjust the number of shares of Common Stock subject to any award, adjust the price of any or all outstanding awards or otherwise waive or change previously imposed terms and conditions, in such circumstances as the Administrator may deem appropriate, in each case subject to Sections 4 and 8.6 (and subject to the no repricing provision below);
(h)    determine the date of grant of an award, which may be a designated date after but not before the date of the Administrator’s action to approve the award (unless otherwise designated by the Administrator, the date of grant of an award shall be the date upon which the Administrator took the action approving the award);
(i)    determine whether, and the extent to which, adjustments are required pursuant to Section 7.1 hereof and take any other actions contemplated by Section 7 in connection with the occurrence of an event of the type described in Section 7;
(j)    acquire or settle (subject to Sections 7 and 8.6) rights under awards in cash, stock of equivalent value, or other consideration (subject to the no repricing provision below); and
(k)    determine the fair market value of the Common Stock or awards under this Plan from time to time and/or the manner in which such value will be determined.
3.3        Prohibition on Repricing.  Notwithstanding anything to the contrary in Section 3.2 and except for an adjustment pursuant to Section 7.1 or a repricing approved by stockholders, in no case may the Administrator (1) amend an outstanding stock option or SAR to reduce the exercise price or base price of the award, (2) cancel, exchange, or surrender an outstanding stock option or SAR in exchange for cash or other awards for the purpose of repricing the award, or (3) cancel, exchange, or surrender an outstanding stock option or SAR in exchange for an option or SAR with an exercise or base price that is less than the exercise or base price of the original award.
3.4        Binding Determinations.  Any determination or other action taken by, or inaction of, the Corporation, any Subsidiary, or the Administrator relating or pursuant to this Plan (or any award made under this Plan) and within its authority hereunder or under applicable law shall be within the absolute discretion of that entity or body and shall be conclusive and binding upon all persons.  Neither the Board nor any other Administrator, nor any member thereof or person acting at the direction thereof, shall be liable for any act, omission, interpretation, construction or determination made in good faith in connection with this Plan (or any award made under this Plan), and all such persons shall be entitled to indemnification and reimbursement by the Corporation in respect of any claim, loss, damage or expense (including, without limitation, attorneys’ fees) arising or resulting therefrom to the fullest extent permitted by law and/or under any directors and officers liability insurance coverage that may be in effect from time to time.  Neither the Board nor any other Administrator, nor any member thereof or person acting at the direction thereof, nor the Corporation or any of its Subsidiaries, shall be liable for any damages of a participant should an option intended as an ISO (as defined below) fail to meet the requirements of the Internal Revenue Code of 1986, as amended (the “Code”), applicable to ISOs, should any other award(s) fail to qualify for any intended tax treatment, should any award grant or other action with respect thereto not satisfy Rule 16b-3 promulgated under the Securities Exchange Act of 1934, as amended, or otherwise for any tax or other liability imposed on a participant with respect to an award.
3.5        Reliance on Experts.  In making any determination or in taking or not taking any action under this Plan, the Administrator may obtain and may rely upon the advice of experts, including employees and professional advisors to the Corporation.  No director, officer or agent of the Corporation or any of its Subsidiaries shall be liable for any such action or determination taken or made or omitted in good faith.

Exhibit 10.1

3.6        Delegation.  The Administrator may delegate ministerial, non-discretionary functions to individuals who are officers or employees of the Corporation or any of its Subsidiaries or to third parties.
3.7        Minimum Vesting Requirement.  Notwithstanding anything to the contrary in Section 3.2 and except as provided in the next sentence, all awards granted under this Plan shall be subject to a minimum vesting requirement for one year, and no portion of any such award may vest earlier than the first anniversary of the grant date of the award (the “Minimum Vesting Requirement”).  The Minimum Vesting Requirement shall not apply to 5% of the total number of shares available under this Plan.
4.    SHARES OF COMMON STOCK SUBJECT TO THE PLAN; SHARE LIMITS
4.1        Shares Available.  Subject to the provisions of Section 7.1, the capital stock that may be delivered under this Plan shall be shares of the Corporation’s authorized but unissued Common Stock and any shares of its Common Stock held as treasury shares.  For purposes of this Plan, “Common Stock” shall mean the common stock of the Corporation and such other securities or property as may become the subject of awards under this Plan, or may become subject to such awards, pursuant to an adjustment made under Section 7.1.
4.2        Aggregate Share Limit.  The maximum number of shares of Common Stock that may be delivered pursuant to awards granted to Eligible Persons under this Plan (the “Share Limit”) is equal to the sum of the following:
(1)    7,713,160 shares of Common Stock, plus
 (2)    the number of any shares subject to stock options granted under the Corporation’s 2012 Equity Incentive Plan, as amended or amended and restated (the “2012 Plan”) and the Corporation’s 2010 Equity Incentive Plan, as amended (the “2010 Plan” and together with the 2012 Plan, the “Prior Plans”) that were outstanding on March 22, 2019 (the date of initial stockholder approval of this Plan, the “Stockholder Approval Date”) which expire, or for any reason are cancelled or terminated, after the Stockholder Approval Date without being exercised, plus
(3)    the number of any shares subject to restricted stock and restricted stock unit awards granted under the Prior Plans that were outstanding and unvested on the Stockholder Approval Date and that are forfeited, terminated, cancelled or otherwise reacquired by the Corporation without having become vested, after the Stockholder Approval Date.
provided that in no event shall the Share Limit exceed 9,006,420 shares (which is the sum of the 7,713,160 shares set forth above, plus the aggregate number of shares subject to awards previously granted and outstanding under the Prior Plans as of the Stockholder Approval Date).
4.3        Additional Share Limits.  The following limits also apply with respect to awards granted under this Plan.  These limits are in addition to, not in lieu of, the aggregate Share Limit in Section 4.2.
(a)              The maximum number of shares of Common Stock that may be delivered pursuant to options qualified as incentive stock options granted under this Plan is 7,713,160 shares.
(b)              Notwithstanding any other provision of the Plan to the contrary, the maximum value of Awards granted under the Plan during a calendar year to a non-employee Director for services on the Board, taken together with any cash fees paid by the Company to such non-employee Director during such calendar year for services on the Board, shall not exceed $800,000 in total value (calculating the value of any such Awards based on the grant date fair value of such Awards), including for this purpose the value of any Awards that are received in lieu of payment of all or a portion of his or her regular annual retainer, additional retainer paid in connection with service on any committee of the Board, or other cash fees.  For purposes of this Section 4.3(b), a “non-employee director” is an individual who, on the grant date of the award, is a member of the Board who is not then an officer or employee of the Corporation or one of its Subsidiaries.  For purposes of this Section 4.3(b), “grant date fair value” means the value of the award as of the date of grant of the award and as determined using the equity award valuation principles applied in the Corporation’s financial reporting.  The limits of this Section 4.3(b) do not apply to, and shall be determined without taking into account, any award granted to an individual who, on the grant date of the award, is an officer or employee of the Corporation or one of its Subsidiaries.  The limits of this Section 4.3(b) apply on an individual basis and not on an aggregate basis to all non-employee directors as a group.
4.4        Share-Limit Counting Rules.  The Share Limit shall be subject to the following provisions of this Section 4.4:
(a)    Shares that are subject to or underlie awards granted under this Plan which expire or for any reason are cancelled or terminated, are forfeited, fail to vest, or for any other reason are not paid or delivered under this Plan shall not be counted against the Share Limit and shall be available for subsequent awards under this Plan.  

Exhibit 10.1

(b)    To the extent that shares of Common Stock are delivered pursuant to the exercise of a stock appreciation right granted under this Plan, the total number of underlying shares subject to such stock appreciation right shall be counted against the Share Limit.  (For purposes of clarity, if a stock appreciation right relates to 100,000 shares and is exercised in full at a time when the payment due to the participant is 15,000 shares, 100,000 shares shall be counted against the Share Limit with respect to such exercise.)  
(c)    Shares that are exchanged by a participant or withheld by the Corporation as full or partial payment in connection with any stock option or stock appreciation right granted under this Plan, as well as any shares exchanged by a participant or withheld by the Corporation or one of its Subsidiaries to satisfy the tax withholding obligations related to any stock option or stock appreciation right granted under this Plan, shall be counted against the Share Limit and shall not be available for subsequent awards under this Plan.  Shares that are exchanged by a participant or withheld by the Corporation as full or partial payment in connection with any “full-value award” granted under this Plan, as well as any shares exchanged by a participant or withheld by the Corporation or one of its Subsidiaries to satisfy the tax withholding obligations related to any full-value award granted under this Plan, shall be counted against the Share Limit and shall not be available for subsequent awards under this Plan.  
(d)    In addition, shares that are exchanged by a participant or withheld by the Corporation after the Stockholder Approval Date as full or partial payment in connection with any award granted under the Prior Plans, as well as any shares exchanged by a participant or withheld by the Corporation or one of its Subsidiaries after the Stockholder Approval Date to satisfy the tax withholding obligations related to any award granted under the Prior Plans, shall not be available for new awards under this Plan. 
(e)    To the extent that an award granted under this Plan is settled in cash or a form other than shares of Common Stock, the shares that would have been delivered had there been no such cash or other settlement shall not be counted against the Share Limit and shall be available for subsequent awards under this Plan. 
(f)    In the event that shares of Common Stock are delivered in respect of a dividend equivalent right granted under this Plan, the number of shares delivered with respect to the award shall be counted against the Share Limit.  (For purposes of clarity, if 1,000 dividend equivalent rights are granted and outstanding when the Corporation pays a dividend, and 50 shares are delivered in payment of those rights with respect to that dividend, 50 shares shall be counted against the Share Limit).  Except as otherwise provided by the Administrator, shares delivered in respect of dividend equivalent rights shall not count against any individual award limit under this Plan other than the aggregate Share Limit.
(g)    The Corporation may not increase the Share Limit by repurchasing shares of Common Stock on the market (by using cash received through the exercise of stock options or otherwise). 
Refer to Section 8.10 for application of the share limits of this Plan, including the limits in Sections 4.2 and 4.3, with respect to assumed awards.  Each of the numerical limits and references in Sections 4.2 and 4.3, and in this Section 4.4, is subject to adjustment as contemplated by Section 4.3, Section 7 and Section 8.10.
4.5    No Fractional Shares; Minimum Issue.  Unless otherwise expressly provided by the Administrator, no fractional shares shall be delivered under this Plan.  The Administrator may pay cash in lieu of any fractional shares in settlements of awards under this Plan.  The Administrator may from time to time impose a limit (of not greater than 100 shares) on the minimum number of shares that may be purchased or exercised as to awards (or any particular award) granted under this Plan unless (as to any particular award) the total number purchased or exercised is the total number at the time available for purchase or exercise under the award.
5.    AWARDS
5.1    Type and Form of Awards.  The Administrator shall determine the type or types of award(s) to be made to each selected Eligible Person.  Awards may be granted singly, in combination or in tandem.  Awards also may be made in combination or in tandem with, in replacement of, as alternatives to, or as the payment form for grants or rights under any other employee or compensation plan of the Corporation or one of its Subsidiaries.  The types of awards that may be granted under this Plan are:
5.1.1    Stock Options.  A stock option is the grant of a right to purchase a specified number of shares of Common Stock during a specified period as determined by the Administrator.  An option may be intended as an incentive stock option within the meaning of Section 422 of the Code (an “ISO”) or a nonqualified stock option (an option not intended to be an ISO).  The agreement evidencing the grant of an option will indicate if the option is intended as an ISO; otherwise it will be deemed to be a nonqualified stock option.  The maximum term of each option (ISO or nonqualified) shall be ten (10) years.  The per share exercise price for each option shall be not less than 100% of the fair market value of a share of Common Stock on the date of grant of the option.  When an option is exercised, the exercise price for the shares to be purchased shall be paid in full in cash or such other method permitted by the Administrator consistent with Section 5.4. 

Exhibit 10.1

5.1.2    Additional Rules Applicable to ISOs.  To the extent that the aggregate fair market value (determined at the time of grant of the applicable option) of stock with respect to which ISOs first become exercisable by a participant in any calendar year exceeds $100,000, taking into account both Common Stock subject to ISOs under this Plan and stock subject to ISOs under all other plans of the Corporation or one of its Subsidiaries (or any parent or predecessor corporation to the extent required by and within the meaning of Section 422 of the Code and the regulations promulgated thereunder), such options shall be treated as nonqualified stock options.  In reducing the number of options treated as ISOs to meet the $100,000 limit, the most recently granted options shall be reduced first.  To the extent a reduction of simultaneously granted options is necessary to meet the $100,000 limit, the Administrator may, in the manner and to the extent permitted by law, designate which shares of Common Stock are to be treated as shares acquired pursuant to the exercise of an ISO.  ISOs may only be granted to employees of the Corporation or one of its subsidiaries (for this purpose, the term “subsidiary” is used as defined in Section 424(f) of the Code, which generally requires an unbroken chain of ownership of at least 50% of the total combined voting power of all classes of stock of each subsidiary in the chain beginning with the Corporation and ending with the subsidiary in question).  No ISO may be granted to any person who, at the time the option is granted, owns (or is deemed to own under Section 424(d) of the Code) shares of outstanding Common Stock possessing more than 10% of the total combined voting power of all classes of stock of the Corporation, unless the exercise price of such option is at least 110% of the fair market value of the stock subject to the option and such option by its terms is not exercisable after the expiration of five years from the date such option is granted.  If an otherwise-intended ISO fails to meet the applicable requirements of Section 422 of the Code, the option shall be a nonqualified stock option.  
5.1.3    Stock Appreciation Rights.  A stock appreciation right or “SAR” is a right to receive a payment, in cash and/or Common Stock, equal to the excess of the fair market value of a specified number of shares of Common Stock on the date the SAR is exercised over the “base price” of the award, which base price shall be set forth in the applicable award agreement and shall be not less than 100% of the fair market value of a share of Common Stock on the date of grant of the SAR.  The maximum term of a SAR shall be ten (10) years.
5.1.4    Other Awards; Dividend Equivalent Rights.  The other types of awards that may be granted under this Plan include: (a) stock bonuses, restricted stock, performance stock, stock units, restricted stock units, deferred shares, phantom stock or similar rights to purchase or acquire shares, whether at a fixed or variable price (or no price) or fixed or variable ratio related to the Common Stock, and, subject to the Minimum Vesting Requirement, any of which may (but need not) be fully vested at grant or vest upon the passage of time, the occurrence of one or more events, the satisfaction of performance criteria or other conditions, or any combination thereof; or (b) cash awards.  The types of cash awards that may be granted under this Plan include the opportunity to receive a payment for the achievement of one or more goals established by the Administrator, on such terms as the Administrator may provide, as well as discretionary cash awards.  Dividend equivalent rights may be granted as a separate award or in connection with another award under this Plan; provided, however, that dividend equivalent rights may not be granted as to a stock option or SAR granted under this Plan.  In addition, any dividends and/or dividend equivalents as to the portion of an award that is subject to unsatisfied vesting requirements will be subject to termination and forfeiture to the same extent as the corresponding portion of the award to which they relate in the event the applicable vesting requirements are not satisfied. 
5.1.5    Performance Goals.  The grant, vesting, exercisability or payment of an award may (but need not) depend on the degree of achievement of one or more performance goals relative to a pre-established targeted level or levels using  business criteria as selected by the Administrator in its sole discretion.
5.2        Award Agreements.  Each award shall be evidenced by a written or electronic award agreement or notice in a form approved by the Administrator (an “award agreement”), and, in each case and if required by the Administrator, executed or otherwise electronically accepted by the recipient of the award in such form and manner as the Administrator may require.
5.3    Deferrals and Settlements.  Payment of awards may be in the form of cash, Common Stock, other awards or combinations thereof as the Administrator shall determine, and with such restrictions (if any) as it may impose.  The Administrator may also require or permit participants to elect to defer the issuance of shares or the settlement of awards in cash under such rules and procedures as it may establish under this Plan.  The Administrator may also provide that deferred settlements include the payment or crediting of interest or other earnings on the deferral amounts, or the payment or crediting of dividend equivalents where the deferred amounts are denominated in shares.
5.4    Consideration for Common Stock or Awards.  The purchase price (if any) for any award granted under this Plan or the Common Stock to be delivered pursuant to an award, as applicable, may be paid by means of any lawful consideration as determined by the Administrator, including, without limitation, one or a combination of the following methods:
(a)        services rendered by the recipient of such award;
(b)        cash, check payable to the order of the Corporation, or electronic funds transfer;

Exhibit 10.1

(c)        notice and third party payment in such manner as may be authorized by the Administrator;
(d)        the delivery of previously owned shares of Common Stock;
(e)        by a reduction in the number of shares otherwise deliverable pursuant to the award; or
(f)        subject to such procedures as the Administrator may adopt, pursuant to a “cashless exercise” with a third party who provides financing for the purposes of (or who otherwise facilitates) the purchase or exercise of awards.
In no event shall any shares newly-issued by the Corporation be issued for less than the minimum lawful consideration for such shares or for consideration other than consideration permitted by applicable state law.  Shares of Common Stock used to satisfy the exercise price of an option shall be valued at their fair market value.  The Corporation will not be obligated to deliver any shares unless and until it receives full payment of the exercise or purchase price therefor and any related withholding obligations under Section 8.5 and any other conditions to exercise or purchase have been satisfied.  Unless otherwise expressly provided in the applicable award agreement, the Administrator may at any time eliminate or limit a participant’s ability to pay any purchase or exercise price of any award or shares by any method other than cash payment to the Corporation.
5.5    Definition of Fair Market Value.  For purposes of this Plan, “fair market value” shall mean, unless otherwise determined or provided by the Administrator in the circumstances, the closing price (in regular trading) for a share of Common Stock on the Nasdaq Stock Market (the “Market”) for the date in question or, if no sales of Common Stock were reported on the Market on that date, the closing price (in regular trading) for a share of Common Stock on the Market for the next preceding day on which sales of Common Stock were reported on the Market.  The Administrator may, however, provide with respect to one or more awards that the fair market value shall equal the closing price (in regular trading) for a share of Common Stock on the Market on the last trading day preceding the date in question or the average of the high and low trading prices of a share of Common Stock on the Market for the date in question or the most recent trading day.  If the Common Stock is no longer listed or is no longer actively traded on the Market as of the applicable date, the fair market value of the Common Stock shall be the value as reasonably determined by the Administrator for purposes of the award in the circumstances.  The Administrator also may adopt a different methodology for determining fair market value with respect to one or more awards if a different methodology is necessary or advisable to secure any intended favorable tax, legal or other treatment for the particular award(s) (for example, and without limitation, the Administrator may provide that fair market value for purposes of one or more awards will be based on an average of closing prices (or the average of high and low daily trading prices) for a specified period preceding the relevant date).
5.6    Transfer Restrictions.
5.6.1    Limitations on Exercise and Transfer.  Unless otherwise expressly provided in (or pursuant to) this Section 5.6 or required by applicable law: (a) all awards are non-transferable and shall not be subject in any manner to sale, transfer, anticipation, alienation, assignment, pledge, encumbrance or charge; (b) awards shall be exercised only by the participant; and (c) amounts payable or shares issuable pursuant to any award shall be delivered only to (or for the account of) the participant.
5.6.2    Exceptions.  The Administrator may permit awards to be exercised by and paid to, or otherwise transferred to, other persons or entities pursuant to such conditions and procedures, including limitations on subsequent transfers, as the Administrator may, in its sole discretion, establish in writing.  Any permitted transfer shall be subject to compliance with applicable federal and state securities laws and shall not be for value (other than nominal consideration, settlement of marital property rights, or for interests in an entity in which more than 50% of the voting interests are held by the Eligible Person or by the Eligible Person’s family members).
5.6.3    Further Exceptions to Limits on Transfer.  The exercise and transfer restrictions in Section 5.6.1 shall not apply to: 
(a)    transfers to the Corporation (for example, in connection with the expiration or termination of the award);
(b)    the designation of a beneficiary to receive benefits in the event of the participant’s death or, if the participant has died, transfers to or exercise by the participant’s beneficiary, or, in the absence of a validly designated beneficiary, transfers by will or the laws of descent and distribution;
(c)    subject to any applicable limitations on ISOs, transfers to a family member (or former family member) pursuant to a domestic relations order if received by the Administrator;
(d)    if the participant has suffered a disability, permitted transfers or exercises on behalf of the participant by his or her legal representative; or

Exhibit 10.1

(e)    the authorization by the Administrator of “cashless exercise” procedures with third parties who provide financing for the purpose of (or who otherwise facilitate) the exercise of awards consistent with applicable laws and any limitations imposed by the Administrator.
5.7    International Awards.  One or more awards may be granted to Eligible Persons who provide services to the Corporation or one of its Subsidiaries outside of the United States.  Any awards granted to such persons may be granted pursuant to the terms and conditions of any applicable sub-plans, if any, appended to this Plan and approved by the Administrator from time to time.  The awards so granted need not comply with other specific terms of this Plan, provided that stockholder approval of any deviation from the specific terms of this Plan is not required by applicable law or any applicable listing agency.
6.    EFFECT OF TERMINATION OF EMPLOYMENT OR SERVICE ON AWARDS
6.1    General.  The Administrator shall establish the effect (if any) of a termination of employment or service on the rights and benefits under each award under this Plan and in so doing may make distinctions based upon, inter alia, the cause of termination and type of award.  If the participant is not an employee of the Corporation or one of its Subsidiaries, is not a member of the Board, and provides other services to the Corporation or one of its Subsidiaries, the Administrator shall be the sole judge for purposes of this Plan (unless a contract or the award otherwise provides) of whether the participant continues to render services to the Corporation or one of its Subsidiaries and the date, if any, upon which such services shall be deemed to have terminated.
6.2    Events Not Deemed Terminations of Employment.  Unless the express policy of the Corporation or one of its Subsidiaries, or the Administrator, otherwise provides, or except as otherwise required by applicable law, the employment relationship shall not be considered terminated in the case of: (a) sick leave, (b) military leave, or (c) any other leave of absence authorized by the Corporation or one of its Subsidiaries, or the Administrator; provided that, unless reemployment upon the expiration of such leave is guaranteed by contract or law or the Administrator otherwise provides, such leave is for a period of not more than three months.  In the case of any employee of the Corporation or one of its Subsidiaries on an approved leave of absence, continued vesting of the award while on leave from the employ of the Corporation or one of its Subsidiaries may be suspended until the employee returns to service, unless the Administrator otherwise provides or applicable law otherwise requires.  In no event shall an award be exercised after the expiration of any applicable maximum term of the award.
6.3    Effect of Change of Subsidiary Status.  For purposes of this Plan and any award, if an entity ceases to be a Subsidiary of the Corporation a termination of employment or service shall be deemed to have occurred with respect to each Eligible Person in respect of such Subsidiary who does not continue as an Eligible Person in respect of the Corporation or another Subsidiary that continues as such after giving effect to the transaction or other event giving rise to the change in status unless the Subsidiary that is sold, spun-off or otherwise divested (or its successor or a direct or indirect parent of such Subsidiary or successor) assumes the Eligible Person’s award(s) in connection with such transaction.
7.    ADJUSTMENTS; ACCELERATION
7.1        Adjustments.  
(a)    Subject to Section 7.2, upon (or, as may be necessary to effect the adjustment, immediately prior to): any reclassification, recapitalization, stock split (including a stock split in the form of a stock dividend) or reverse stock split; any merger, combination, consolidation, conversion or other reorganization; any spin-off, split-up, or similar extraordinary dividend distribution in respect of the Common Stock; or any exchange of Common Stock or other securities of the Corporation, or any similar, unusual or extraordinary corporate transaction in respect of the Common Stock; then the Administrator shall equitably and proportionately adjust: (1) the number and type of shares of Common Stock (or other securities) that thereafter may be made the subject of awards (including the specific share limits, maximums and numbers of shares set forth elsewhere in this Plan); (2) the number, amount and type of shares of Common Stock (or other securities or property) subject to any outstanding awards; (3) the grant, purchase, or exercise price (which term includes the base price of any SAR or similar right) of any outstanding awards; and/or (4) the securities, cash or other property deliverable upon exercise or payment of any outstanding awards, in each case to the extent necessary to preserve (but not increase) the level of incentives intended by this Plan and the then-outstanding awards.
(b)    Without limiting the generality of Section 3.4, any good faith determination by the Administrator as to whether an adjustment is required in the circumstances pursuant to this Section 7.1, and the extent and nature of any such adjustment, shall be conclusive and binding on all persons.
7.2        Corporate Transactions - Assumption and Termination of Awards.  
(a)    Upon any event in which the Corporation does not survive, or does not survive as a public company in respect of its Common Stock (including, without limitation, a dissolution, merger, combination, consolidation, conversion, 

Exhibit 10.1

exchange of securities, or other reorganization, or a sale of all or substantially all of the business, stock or assets of the Corporation, in any case in connection with which the Corporation does not survive or does not survive as a public company in respect of its Common Stock), then the Administrator may make provision for a cash payment in settlement of, or for the termination, assumption, substitution or exchange of any or all outstanding awards or the cash, securities or property deliverable to the holder of any or all outstanding awards, based upon, to the extent relevant under the circumstances, the distribution or consideration payable to holders of the Common Stock upon or in respect of such event.  Upon the occurrence of any event described in the preceding sentence in connection with which the Administrator has made provision for the award to be terminated (and the Administrator has not made a provision for the substitution, assumption, exchange or other continuation or settlement of the award): (1) unless otherwise provided in the applicable award agreement, each then-outstanding option and SAR shall become fully vested, all shares of restricted stock then outstanding shall fully vest free of restrictions, and each other award granted under this Plan that is then outstanding shall become payable to the holder of such award (with any performance goals applicable to the award in each case being deemed met, unless otherwise provided in the award agreement, at the “target” performance level); and (2) each award (including any award or portion thereof that, by its terms, does not accelerate and vest in the circumstances) shall terminate upon the related event; provided that the holder of an option or SAR shall be given reasonable advance notice of the impending termination and a reasonable opportunity to exercise his or her outstanding vested options and SARs (after giving effect to any accelerated vesting required in the circumstances) in accordance with their terms before the termination of such awards (except that in no case shall more than ten days’ notice of the impending termination be required and any acceleration of vesting and any exercise of any portion of an award that is so accelerated may be made contingent upon the actual occurrence of the event).
(b)    Without limiting the preceding paragraph, in connection with any event referred to in the preceding paragraph or any change in control event defined in any applicable award agreement, the Administrator may, in its discretion, provide for the accelerated vesting of any award or awards as and to the extent determined by the Administrator in the circumstances.
(c)    For purposes of this Section 7.2, an award shall be deemed to have been “assumed” if (without limiting other circumstances in which an award is assumed) the award continues after an event referred to above in this Section 7.2, and/or is assumed and continued by the surviving entity following such event (including, without limitation, an entity that, as a result of such event, owns the Corporation or all or substantially all of the Corporation’s assets directly or through one or more subsidiaries (a “Parent”)), and confers the right to purchase or receive, as applicable and subject to vesting and the other terms and conditions of the award, for each share of Common Stock subject to the award immediately prior to the event, the consideration (whether cash, shares, or other securities or property) received in the event by the stockholders of the Corporation for each share of Common Stock sold or exchanged in such event (or the consideration received by a majority of the stockholders participating in such event if the stockholders were offered a choice of consideration); provided, however, that if the consideration offered for a share of Common Stock in the event is not solely the ordinary common stock of a successor corporation or a Parent, the Administrator may provide for the consideration to be received upon exercise or payment of the award, for each share subject to the award, to be solely ordinary common stock of the successor corporation or a Parent equal in fair market value to the per share consideration received by the stockholders participating in the event.
(d)    The Administrator may adopt such valuation methodologies for outstanding awards as it deems reasonable in the event of a cash or property settlement and, in the case of options, SARs or similar rights, but without limitation on other methodologies, may base such settlement solely upon the excess if any of the per share amount payable upon or in respect of such event over the exercise or base price of the award. In the case of an option, SAR or similar right as to which the per share amount payable upon or in respect of such event is less than or equal to the exercise or base price of the award, the Administrator may terminate such award in connection with an event referred to in this Section 7.2 without any payment in respect of such award.
(e)    In any of the events referred to in this Section 7.2, the Administrator may take such action contemplated by this Section 7.2 prior to such event (as opposed to on the occurrence of such event) to the extent that the Administrator deems the action necessary to permit the participant to realize the benefits intended to be conveyed with respect to the underlying shares.  Without limiting the generality of the foregoing, the Administrator may deem an acceleration and/or termination to occur immediately prior to the applicable event and, in such circumstances, will reinstate the original terms of the award if an event giving rise to an acceleration and/or termination does not occur. 
(f)    Without limiting the generality of Section 3.4, any good faith determination by the Administrator pursuant to its authority under this Section 7.2 shall be conclusive and binding on all persons. 
(g)    The Administrator may override the provisions of this Section 7.2 by express provision in the award agreement and may accord any Eligible Person a right to refuse any acceleration, whether pursuant to the award agreement or otherwise, in such circumstances as the Administrator may approve.  The portion of any ISO accelerated in connection with an event referred to in this Section 7.2 (or such other circumstances as may trigger accelerated vesting of the award) shall remain exercisable as an ISO only to the extent the applicable $100,000 limitation on ISOs is not exceeded.  To the extent exceeded, the accelerated portion of the option shall be exercisable as a nonqualified stock option under the Code.

Exhibit 10.1

8.    OTHER PROVISIONS
8.1    Compliance with Laws.  This Plan, the granting and vesting of awards under this Plan, the offer, issuance and delivery of shares of Common Stock, and/or the payment of money under this Plan or under awards are subject to compliance with all applicable federal, state, local and foreign laws, rules and regulations (including, but not limited to, state and federal securities law and federal margin requirements) and to such approvals by any listing, regulatory or governmental authority as may, in the opinion of counsel for the Corporation, be necessary or advisable in connection therewith.  The person acquiring any securities under this Plan will, if requested by the Corporation or one of its Subsidiaries, provide such assurances and representations to the Corporation or one of its Subsidiaries as the Administrator may deem necessary or desirable to assure compliance with all applicable legal and accounting requirements.
8.2    No Rights to Award.  No person shall have any claim or rights to be granted an award (or additional awards, as the case may be) under this Plan, subject to any express contractual rights (set forth in a document other than this Plan) to the contrary.
8.3    No Employment/Service Contract.  Nothing contained in this Plan (or in any other documents under this Plan or in any award) shall confer upon any Eligible Person or other participant any right to continue in the employ or other service of the Corporation or one of its Subsidiaries, constitute any contract or agreement of employment or other service or affect an employee’s status as an employee at will, nor shall interfere in any way with the right of the Corporation or one of its Subsidiaries to change a person’s compensation or other benefits, or to terminate his or her employment or other service, with or without cause.  Nothing in this Section 8.3, however, is intended to adversely affect any express independent right of such person under a separate employment or service contract other than an award agreement.
8.4    Plan Not Funded.  Awards payable under this Plan shall be payable in shares or from the general assets of the Corporation, and no special or separate reserve, fund or deposit shall be made to assure payment of such awards.  No participant, beneficiary or other person shall have any right, title or interest in any fund or in any specific asset (including shares of Common Stock, except as expressly otherwise provided) of the Corporation or one of its Subsidiaries by reason of any award hereunder.  Neither the provisions of this Plan (or of any related documents), nor the creation or adoption of this Plan, nor any action taken pursuant to the provisions of this Plan shall create, or be construed to create, a trust of any kind or a fiduciary relationship between the Corporation or one of its Subsidiaries and any participant, beneficiary or other person.  To the extent that a participant, beneficiary or other person acquires a right to receive payment pursuant to any award hereunder, such right shall be no greater than the right of any unsecured general creditor of the Corporation.
8.5    Tax Withholding.  Upon any exercise, vesting, or payment of any award, or upon the disposition of shares of Common Stock acquired pursuant to the exercise of an ISO prior to satisfaction of the holding period requirements of Section 422 of the Code, or upon any other tax withholding event with respect to any award, arrangements satisfactory to the Corporation shall be made to provide for any taxes the Corporation or any of its Subsidiaries may be required or permitted to withhold with respect to such award event or payment.  Such arrangements may include (but are not limited to) any one of (or a combination of) the following:
(a)             The Corporation or one of its Subsidiaries shall have the right to require the participant (or the participant’s personal representative or beneficiary, as the case may be) to pay or provide for payment of the amount of any taxes which the Corporation or one of its Subsidiaries may be required or permitted to withhold with respect to such award event or payment.
(b)             The Corporation or one of its Subsidiaries shall have the right to deduct from any amount otherwise payable in cash (whether related to the award or otherwise) to the participant (or the participant’s personal representative or beneficiary, as the case may be) the amount of any taxes which the Corporation or one of its Subsidiaries may be required or permitted to withhold with respect to such award event or payment.
(c)    In any case where a tax is required to be withheld in connection with the delivery of shares of Common Stock under this Plan, the Administrator may in its sole discretion (subject to Section 8.1) require or grant (either at the time of the award or thereafter) to the participant the right to elect, pursuant to such rules and subject to such conditions as the Administrator may establish, that the Corporation reduce the number of shares to be delivered by (or otherwise reacquire) the appropriate number of shares, valued in a consistent manner at their fair market value or at the sales price in accordance with authorized procedures for cashless exercises, necessary to satisfy any applicable withholding obligation on exercise, vesting or payment.
8.6    Effective Date, Termination and Suspension, Amendments.
8.6.1    Effective Date.  This Plan was originally effective as of December 14, 2018, the date of its original approval by the Board (the “Effective Date”).  This amended version of this Plan is effective as of December 9, 2021, the date this amended version of this Plan was approved by the Board (the “Amendment Date”).  This Plan 

Exhibit 10.1

shall be submitted for and subject to stockholder approval no later than twelve months after the Amendment Date.  Unless earlier terminated by the Board and subject to any extension that may be approved by stockholders, this Plan shall terminate at the close of business on December 9, 2028.  After the termination of this Plan either upon such stated termination date or its earlier termination by the Board, no additional awards may be granted under this Plan, but previously granted awards (and the authority of the Administrator with respect thereto, including the authority to amend such awards) shall remain outstanding in accordance with their applicable terms and conditions and the terms and conditions of this Plan.
8.6.2    Board Authorization.  The Board may, at any time, terminate or, from time to time, amend, modify or suspend this Plan, in whole or in part.  No awards may be granted during any period that the Board suspends this Plan.
8.6.3    Stockholder Approval.  To the extent then required by applicable law or deemed necessary or advisable by the Board, any amendment to this Plan shall be subject to stockholder approval.
8.6.4    Amendments to Awards.  Without limiting any other express authority of the Administrator under (but subject to) the express limits of this Plan, the Administrator by agreement or resolution may waive conditions of or limitations on awards to participants that the Administrator in the prior exercise of its discretion has imposed, without the consent of a participant, and (subject to the requirements of Sections 3.2 and 8.6.5) may make other changes to the terms and conditions of awards.  Any amendment or other action that would constitute a repricing of an award is subject to the no-repricing provision of Section 3.3.
8.6.5    Limitations on Amendments to Plan and Awards.  No amendment, suspension or termination of this Plan or amendment of any outstanding award agreement shall, without written consent of the participant, affect in any manner materially adverse to the participant any rights or benefits of the participant or obligations of the Corporation under any award granted under this Plan prior to the effective date of such change.  Changes, settlements and other actions contemplated by Section 7 shall not be deemed to constitute changes or amendments for purposes of this Section 8.6.
8.7    Privileges of Stock Ownership.  Except as otherwise expressly authorized by the Administrator, a participant shall not be entitled to any privilege of stock ownership as to any shares of Common Stock not actually delivered to and held of record by the participant.  Except as expressly required by Section 7.1 or otherwise expressly provided by the Administrator, no adjustment will be made for dividends or other rights as a stockholder for which a record date is prior to such date of delivery.
8.8    Governing Law; Severability.
8.8.1    Choice of Law.  This Plan, the awards, all documents evidencing awards and all other related documents shall be governed by, and construed in accordance with the laws of the State of New Jersey, notwithstanding any New Jersey or other conflict of law provision to the contrary.
8.8.2    Severability.  If a court of competent jurisdiction holds any provision invalid and unenforceable, the remaining provisions of this Plan shall continue in effect.
8.9    Captions.  Captions and headings are given to the sections and subsections of this Plan solely as a convenience to facilitate reference.  Such headings shall not be deemed in any way material or relevant to the construction or interpretation of this Plan or any provision thereof.    
8.10    Stock-Based Awards in Substitution for Stock Options or Awards Granted by Other Corporation.  Awards may be granted to Eligible Persons in substitution for or in connection with an assumption of employee stock options, SARs, restricted stock or other stock-based awards granted by other entities to persons who are or who will become Eligible Persons in respect of the Corporation or one of its Subsidiaries, in connection with a distribution, merger or other reorganization by or with the granting entity or an affiliated entity, or the acquisition by the Corporation or one of its Subsidiaries, directly or indirectly, of all or a substantial part of the stock or assets of the employing entity.  The awards so granted need not comply with other specific terms of this Plan, provided the awards reflect adjustments giving effect to the assumption or substitution consistent with any conversion applicable to the common stock (or the securities otherwise subject to the award) in the transaction and any change in the issuer of the security.  Any shares that are delivered and any awards that are granted by, or become obligations of, the Corporation, as a result of the assumption by the Corporation of, or in substitution for, outstanding awards previously granted or assumed by an acquired company (or previously granted or assumed by a predecessor employer (or direct or indirect parent thereof) in the case of persons that become employed by the Corporation or one of its Subsidiaries in connection with a business or asset acquisition or similar transaction) shall not be counted against the Share Limit or other limits on the number of shares available for issuance under this Plan.

Exhibit 10.1

8.11    Non-Exclusivity of Plan.  Nothing in this Plan shall limit or be deemed to limit the authority of the Board or the Administrator to grant awards or authorize any other compensation, with or without reference to the Common Stock, under any other plan or authority.
8.12           No Corporate Action Restriction.  The existence of this Plan, the award agreements and the awards granted hereunder shall not limit, affect, or restrict in any way the right or power of the Corporation or any Subsidiary (or any of their respective shareholders, boards of directors or committees thereof (or any subcommittees), as the case may be) to make or authorize: (a) any adjustment, recapitalization, reorganization or other change in the capital structure or business of the Corporation or any Subsidiary, (b) any merger, amalgamation, consolidation or change in the ownership of the Corporation or any Subsidiary, (c) any issue of bonds, debentures, capital, preferred or prior preference stock ahead of or affecting the capital stock (or the rights thereof) of the Corporation or any Subsidiary, (d) any dissolution or liquidation of the Corporation or any Subsidiary, (e) any sale or transfer of all or any part of the assets or business of the Corporation or any Subsidiary, (f) any other award, grant, or payment of incentives or other compensation under any other plan or authority (or any other action with respect to any benefit, incentive or compensation), or (g) any other corporate act or proceeding by the Corporation or any Subsidiary.  No participant, beneficiary or any other person shall have any claim under any award or award agreement against any member of the Board or the Administrator, or the Corporation or any employees, officers or agents of the Corporation or any Subsidiary, as a result of any such action.  Awards need not be structured so as to be deductible for tax purposes.
8.13    Other Company Benefit and Compensation Programs.  Payments and other benefits received by a participant under an award made pursuant to this Plan shall not be deemed a part of a participant’s compensation for purposes of the determination of benefits under any other employee welfare or benefit plans or arrangements, if any, provided by the Corporation or any Subsidiary, except where the Administrator expressly otherwise provides or authorizes in writing.  Awards under this Plan may be made in addition to, in combination with, as alternatives to or in payment of grants, awards or commitments under any other plans, arrangements or authority of the Corporation or its Subsidiaries.
8.14    Clawback Policy.  The awards granted under this Plan are subject to the terms of the Corporation’s recoupment, clawback or similar policy as it may be in effect from time to time, as well as any similar provisions of applicable law, any of which could in certain circumstances require repayment or forfeiture of awards or any shares of Common Stock or other cash or property received with respect to the awards (including any value received from a disposition of the shares acquired upon payment of the awards).
8.15    Administrative Discretion.  Notwithstanding Section 3.7, the Minimum Vesting Requirement shall not limit or restrict the Administrator’s discretion to accelerate the vesting of any awards granted under this Plan in circumstances it determines to be appropriate (whether in connection with a transaction, termination of employment or for any other reason).Exhibit 4.2
​
CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN EXCLUDED PURSUANT TO THE INSTRUCTIONS TO FORM 20-F AND SEC RULES AND REGULATIONS. SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF DISCLOSED.
​
OEM SUPPLY & DEVELOPMENT AGREEMENT
​
This Agreement is made and entered into by and between Olink Proteomics AB, a Swedish corporation with its principal place of business at Dag Hammarskjölds väg 52B, SE-752 37 Uppsala, Sweden (hereinafter referred to as “Olink”), and Fluidigm Corporation, a Delaware corporation organized and existing under the laws of the United States of America, with its principal office at Two Tower Place, Suite 2000, South San Francisco, CA 94080 USA (hereinafter referred to as “Fluidigm”).
​
RECITALS:
​
WHEREAS, Fluidigm designs and manufactures innovative technologies and life-science tools designed to improve life through comprehensive health insight;
​
WHEREAS, Olink is a life sciences company that provides innovative solutions for targeted human protein biomarker discovery;
​
WHEREAS, the Parties desire to work together to develop a new instrument system that includes hardware and instrument operating software (“Biomark O”), develop new Standalone Analysis Software (as defined below) for the Biomark O system and a new integrated fluidic circuit (“IFC”) to support Olink Assay (as defined below) panels (the “Flex IFC”); the Parties will also work together to validate the Supported IFCs (collectively, the “Project”);
​
WHEREAS, Fluidigm desires to manufacture and supply Products; and
​
NOW, THEREFORE, in consideration of the premises of the mutual covenants and agreements herein contained, the parties hereto agree as follows:
​
	1.
	Definitions

​
The following terms as used in this Agreement shall have the meanings set forth below or the meaning as designated in the indicated places throughout this Agreement:
​
1.1.“Accepted” has the meaning set forth in Exhibit D (Product Development Project).
​
1.2.“Account Manager” has the meaning set forth in Section 4.1.
​
1.3.“Annual Maintenance Fee” has the meaning set forth in Section 6.8.1.
​
1.4.“Applicable Laws” shall mean the applicable provisions of any and all national, regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, guidance, ordinances, judgments, decrees, directives, injunctions, orders, permits (including marketing approvals) of or from any court, arbitrator, regulatory agency or governmental agency or authority having jurisdiction over or related to the subject item.
​
1.5.“Approval” shall have the meaning set forth in Section 2.5.
​
​

1
​

1.6.“Background IP” shall mean IP (as defined below) of a Party that is (a) proprietary to that Party and was conceived, created, or developed prior to, or independent of, any research performed under this Agreement or a Work Plan hereunder; and is (b) necessary or useful for the performance of the Project, as disclosed in the Work Plan.
​
1.7.“Biomark O” shall have the meaning set forth in the Recitals.
​
1.8.“Change of Control” means any of the following events: (a) any third party (or group of third parties acting in concert) becomes the beneficial owner, directly or indirectly, of more than fifty percent (50%) of the total voting power of the stock then outstanding of Fluidigm normally entitled to vote in elections of directors; (b) Fluidigm consolidates with or merges into another corporation or entity, or any corporation or entity consolidates with or merges into Fluidigm, in either event pursuant to a transaction in which more than fifty percent (50%) of the total voting power of the stock outstanding of the surviving entity normally entitled to vote in elections of directors is not held by the parties holding at least fifty percent (50%) of the outstanding shares of Fluidigm preceding such consolidation or merger; or (c) Fluidigm conveys, transfers or leases all or substantially all of its assets to any third party.
​
1.9.“Confidential Information” shall have the meaning set forth in Section 16.1.
​
1.10.“Cure Period” shall have the meaning set forth in Section 17.2
​
1.11.“Current IFCs” shall mean [***].
​
1.12.“Current Instruments” shall mean [***].
​
1.13.“Developed Product(s)”shall mean [***].
​
1.14.“Disclosing Party” shall have the meaning set forth in Section 16.1.
​
1.15.“Discretionary Validation” shall have the meaning set forth in Section 6.13.
​
1.16.“Documentation” shall mean any documentation or materials provided or made available by Fluidigm to Olink under this Agreement, including documentation and materials describing the Products.
​
1.17.“Effective Date” shall mean March 31, 2020.
​
1.18.“Escrow Materials” shall have the meaning set forth in Section 19.1.
​
1.19.“FCPA” shall have the meaning set forth in Section 24.
​
1.20.“FDA” shall have the meaning set forth in Section 2.5.
​
1.21.“Feasibility Test” shall have the meaning set forth in Exhibit D (Product Development Project).
​
1.22.“Field of Use” shall mean [***].
​
1.23.“Final Buy” shall have the meaning set forth in Section 18.4.
​
1.24.“Flex IFC” shall have the meaning set forth in the Recitals.
​
1.25.“Fluidigm Indemnified Parties” shall have the meaning set forth in Section 13.1.
​
1.26.“Force Majeure” or “Force Majeure Event” shall have the meaning set forth in Section 14.
​

2
​

1.27.“Forecast” shall have the meaning set forth in Section 7.1.
​
1.28.“FSE” shall have the meaning set forth in Exhibit B (Services).
​
1.29.“Initial Term” shall have the meaning set forth in Section 17.1.
​
1.30.“Instrument” shall mean the Biomark O system developed for the Project hereunder, branded for Olink by Fluidigm, in accordance with terms defined in the Agreement, and as set forth in Exhibit A (Products) attached hereto.
​
1.31.“Instrument Training” shall have the meaning set forth in Exhibit B (Services).
​
1.32.“Intellectual Property” or “IP” shall mean any and all issued patents and pending patent applications (including any provisionals, divisionals, substitutions, renewals, conversions, continuations in whole or in part, reissues, reexaminations, or extensions thereof, and to any letters patent and registrations which may hereafter be granted on any of the foregoing in any countries throughout the world), copyrights (including, but not limited to, rights in audiovisual works and moral rights), mask work rights, trade secrets, confidential information, trademarks, trade names, symbols, logos, brand names, domain names, Know- How and other intellectual property rights in any country of the world or rights having the equivalent effect, along with any associated goodwill of the foregoing.
​
1.33.“IFC(s)” shall have the meaning set forth in the Recitals.
​
1.34.“Instrument Warranty Period” shall have the meaning set forth in Section 9.3.
​
1.35.“In-Term Manufacturing License” shall have the meaning set forth in Section 18.3.
​
1.36.“Invention” shall mean any invention, discovery, design or improvement, conceived or first actually reduced to practice solely or jointly by one or more employees of one or more of the Parties during the term of this Agreement and in the performance of the Work Plan.
​
1.37.“Know-How” shall mean all ideas, concepts, schemes, information, knowledge, techniques, and methodology relating to the manufacture and use of the Products.
​
1.38.“Manufacturing Continuity Plan” shall mean a plan setting forth measures and implementation efforts reasonably designed to (a) identify and set forth plans to implement risk mitigation measures (e.g., identifying available alternative suppliers, infrastructure and inventory management and security and protective measures) reasonably necessary to ensure minimal impact from a range of potential disruptive events on supply of Product, taking into consideration the obligations to supply under this Agreement; (b) anticipate an unplanned or unanticipated disruptive event in order to restore supply continuity; and (c) recover the capacity to Manufacture and deliver Product as promptly as reasonably practicable. The Manufacturing Continuity Plan shall identify key personnel, resources, services and actions which are reasonably anticipated to be required to manage the recovery process.
​
1.39.“Manufacturing Forecast” shall have the meaning set forth in Section 7.1.2.
​
1.40.“Manufacturing Process” shall mean, with respect to a Product, the process, tools, equipment and ingredients, and methods, steps, parameters and other specifications for using the foregoing, and all Documentation and Know-How relating to any of the foregoing, which cover the then current production process enabling a man skilled in the art to establish and run the production process for the manufacture such Product.
​
1.41.“Multiomics” shall mean [***].
​
​

3
​

1.42.“Multiomics Use” shall mean [***].
​
1.43.“New Products” shall have the meaning set forth in Exhibit F (New Products and Product Improvements).
​
1.44.“New Projects” shall have the meaning set forth in Exhibit F (New Products and Product Improvements).
​
1.45.“NRE Payments” shall have the meaning set forth in Section 6.12.
​
1.46.“NPX” shall mean normalized protein expression.
​
1.47.“NPX Manager” shall mean [***].
​
1.48.“Olink Panels” shall mean Olink’s PEA-based immuno-PCR protein expression assay panels.
​
1.49.“Olink Election Notice” shall have the meaning set forth in Section 18.4.
​
1.50.“Olink Indemnified Parties” shall have the meaning set forth in Section 12.1
​
1.51.“Parties” shall mean both Olink and Fluidigm and “Party” shall mean either Olink or Fluidigm.
​
1.52.“PCR” shall have the meaning set forth in Section 1.22.
​
1.53.“PEA” shall have the meaning set forth in Section 1.22.
​
1.54.“Post-Term Manufacturing License” shall have the meaning set forth in Section 18.4.
​
1.55.“Product(s)” shall mean any goods sold by Fluidigm to Olink under this Agreement.
​
1.56.“Product Prices” shall have the meaning set forth in Section 6.5.
​
1.57.“Production Unit” shall have the meaning set forth in 6.13.
​
1.58.“Project” shall have the meaning set forth in the Recitals.
​
1.59.“Project IP” shall mean all Intellectual Property rights and information, including but not limited to all Inventions, Know-How, trade secrets, improvements, data, information, ideas, reports, techniques, methods, drawings, solutions, equipment, designs, or materials, models or improvements reduced to practice in the performance of the Work Plan.
​
1.60.“Reagents” shall mean accessories required for use of the Supported IFCs (as defined in Exhibit A (Products)) with Olink Panels (as defined in Exhibit A (Products)), including, control line fluid, assay loading reagent, and sample loading reagent.
​
1.61.“Recall” shall have the meaning set forth in Section 4.6.
​
1.62.“Recipient” shall have the meaning set forth in Section 16.1.
​
1.63.“Regulatory Laws” shall have the meaning set forth in Section 2.5.
​
1.64.“Release Condition” shall have the meaning set forth in Section 19.1.
​
1.65.“Services” shall mean the services provided under this Agreement, as set forth in Exhibit B
​

4
​

(Services) attached hereto.
​
1.66.“Sales Initiation Quarter” shall have the meaning set forth in Section 6.8.
​
1.67.“SDS” shall have the set forth in Section E (Product Branding, Packaging and Labeling).
​
1.68.“Spare Parts” shall mean any or all parts and/or components assembled or incorporated into the Instruments.
​
1.69.“Specifications” shall means (i) Fluidigm’s specifications for its Current IFCs and Current Instruments; or (ii) the specifications for the Developed Product, as established by inclusion in the Product Requirements Document, described in Exhibit D (Product Development Project), and such other specifications for packaging, storage conditions and labeling of the Developed Product, as agreed by the Parties pursuant to this Agreement.
​
1.70.“Standalone Analysis Software” shall mean [***].
​
1.71.“Supported IFCs” shall have the meaning set forth in Exhibit A (Products).
​
1.72.“Territory” shall mean worldwide.
​
1.73.“Training Class Details” shall have the meaning set forth in Exhibit B (Services).
​
1.74.“United States” or “US” shall mean the United States of America, including its territories and possessions and the District of Columbia.
​
1.75.“US PPI” shall have the meaning set forth in Exhibit B (Services).
​
1.76.“Work Plan” shall mean work plan outlined in Exhibit D (Product Development Project).
​
	2.
	Development; License; and Use

​
2.1.Development, Manufacture, and Sale of Developed Products. Subject to the terms and conditions of this Agreement, during the Term, Fluidigm agrees to develop, manufacture, and sell the Developed Products exclusively to Olink. All Developed Products developed under this Agreement will be designed in accordance with ISO 13485. Fluidigm agrees to develop the Developed Products for the Project as set forth in the Work Plan, and shall meet the Project deadlines as set forth in the Exhibit D. For clarity, Fluidigm reserves the right to develop, manufacture and sell Developed Products similar to the Developed Products that are not branded for Olink outside the Field of Use, but not for Multiomics Use.
​
2.2.Manufacture, and Sale of Current IFCs and Current Instruments. Subject to the terms and conditions of this Agreement, during the Term, Fluidigm agrees to manufacture and sell to Olink: (i) the Current IFCs; and (ii) the Current Instruments, provided they are still manufactured by Fluidigm.
​
2.3.License to Fluidigm’s IP. Fluidigm hereby grants Olink, a royalty free, perpetual, non-exclusive, right under Fluidigm’s Background IP and any Fluidigm held Project IP solely to use and/or sell the Products including, but not limited to, the Instruments and Current Instruments (directly or indirectly) within the Field of Use and during the Term.
​
2.4.Use of Products.  [***]
​
2.5.Certain Use Restrictions.  [***]
​
	3.
	Intellectual Property

​
​

5
​

3.1.Ownership. [***]
​
3.1.1.Background IP. [***]
​
3.1.2.Standalone Analysis Software. [***]
​
3.1.3.Project IP. [***]
​
3.2.Applicable to Personnel Invention Assignment Agreements. [***]
​
3.3.Open Source Software. [***]
​
	4.
	General Obligations

​
4.1.Account Manager. Each Party will designate a single point of contact within its organization to manage the relationship established by this Agreement (“Account Manager”). Either Party may change its Account Manager by providing written notice to the other Party. The Account Managers will meet as necessary to discuss the business relationship and manage the activities contemplated by this Agreement. Disputes that cannot be resolved by the Account Managers will be escalated to more senior executives for resolution. The Parties agree to exchange contact information and instructions for the placement of orders, invoices, and payments in writing within ten (10) days of the Agreement’s Effective Date. Each Party shall provide written notice to the other Party if the contact information changes during the term of the Agreement.
​
4.2.Advertising and Marketing Practices. In advertising and marketing of Products and otherwise performing under this Agreement, Olink will:
​
4.2.1.not engage in any deceptive, misleading, illegal, or unethical practices;
​
		4.2.2.
	not make any representations, warranties, or guarantees concerning the Products that are inconsistent with or in addition to those made by Fluidigm in this Agreement; and

​
4.2.3.comply with all applicable federal, state, and local laws and regulations.
​
4.3.Training. Olink will take reasonable steps to ensure that its sales, distribution, and support representatives receive appropriate training relating to the Products.
​
4.4.Export Restrictions. Olink will obtain all necessary permits and licenses as may be required by, and conforming with, all Applicable Laws prior to making the Products available, and all laws, rules and regulations relating to the sale and/or export of the Products. Olink represents and warrants that Olink is not designated on the United States Commerce Department’s Bureau of Industry and Security Denied Persons List. Where Fluidigm is the exporter of record, Fluidigm shall obtain all necessary permits and licenses as may be required by, and conforming with, all Applicable Laws and all laws, rules, and regulations relating to the sale and/or export of the Products. Fluidigm represents and warrants that Fluidigm is not designated on the United States Commerce Department’s Bureau of Industry and Security Denied Persons List.
​
4.5.Quality. Olink shall be solely responsible for responding to, and addressing all, customer complaints related to the Products. Olink shall report to Fluidigm all customer material formal complaints related to any quality or performance deviation from the Specifications. Olink shall keep a record of all material formal written and oral complaints concerning deviations from the Specifications.
​
4.6.Recalls. Each Party shall, within forty-five (45) business days, inform the other Party of all known Product defects, safety problems or any information associated with the safety of the Products
​

6
​

​
and shall notify the other Party, within forty-five (45) business days, in writing of any third party dispute involving a Product. In the event Fluidigm or any governmental entity decides to recall, replace, or take other action (collectively, a “Recall”) with respect to any Products, Fluidigm will notify Olink of the Recall and Olink will immediately cease distribution of any units of Product incorporating such Products in its possession or control, which are subject to the Recall until the course of action to be taken has been determined. During the Term, Olink and Fluidigm shall discuss a plan for performing any required Recall or market withdrawal of the Products. Olink will maintain traceability records to ensure that each Product can be located at an end-user customer site. In the event Fluidigm initiates a voluntary or mandatory Recall of any Product, Fluidigm will be responsible for bringing its Products into compliance with Applicable Laws, including all regulatory statutes, and will bear costs necessary to do so.
​
4.7.Manufacturing Continuity Plan. Fluidigm shall maintain its existing Manufacturing Continuity Plan related to the Products during the Term. Fluidigm shall deliver a Manufacturing Continuity Plan to Olink for review within twelve (12) months from the execution of this Agreement. Thereafter, Fluidigm shall, not less than annually, review and update (to the extent Fluidigm determines any updates are necessary) the Manufacturing Continuity Plan and, upon Olink’s request, Fluidigm will make the Manufacturing Continuity Plan available to Olink or its designated representatives for review. Fluidigm shall notify Olink in the event it determines updates are not necessary, within thirty (30) days of making such determination.
​
	5.
	Shipping and Delivery

​
5.1.Delivery Dates. Olink’s purchase orders shall specify a delivery date at least ninety (90) days after the date of the purchase order. Olink acknowledges that Fluidigm may not be able to fulfill any purchase orders with a delivery date with less than ninety (90) days lead-time and Fluidigm shall have no liability for said inability. Olink shall not make any changes to a purchase order previously received and accepted by Fluidigm without the prior written consent of Fluidigm.
​
5.2.Shipping. Fluidigm agrees to ship Products to Olink directly in accordance with information provided on a purchase order from Olink. Olink is responsible for costs and delays associated with misdelivery of Product if the information provided to Fluidigm is incomplete or incorrect. Fluidigm is responsible for costs and delays associated with misdelivery of Product if Fluidigm does not follow purchase order instructions. Olink agrees to pay all  shipping charges associated with shipment and delivery of Product.
​
5.3.Freight Notification. Olink shall notify Fluidigm of the freight carrier to use for Product shipments. If Olink does not provide Fluidigm with a chosen freight carrier, Fluidigm may use a freight carrier from Fluidigm’s approved supplier list to process Product shipments in accordance with the purchase order.
​
5.4.Storage. If at any time Olink requests delay in delivery of any shipment, Olink shall submit a request to Fluidigm to store the Products at its facilities and Fluidigm will provide Olink with a quote that includes all charges and all expenses related to such storage. Fluidigm shall not be required to store any such delayed shipment unless the Parties mutually agree on the charges and expenses related to such storage.
​
5.5.Packaging. Fluidigm shall supply normal packing for underdeck export shipment, container shipment or air freight, as may be applicable. Special packing will be provided only if agreed to in writing by Fluidigm and will be at Olink’s expense.
​
5.6.Customs. Customs duties, taxes, and similar charges which may be imposed by the country of shipment shall be borne by Fluidigm. Customs duties, taxes, and similar charges which may occur upon importation shall be paid by Olink and any such costs prepaid by Fluidigm shall be invoiced to Olink.
​
​

7
​

​
5.7.Delivery, Acceptance, and Title. Unless otherwise expressly agreed to in writing by Fluidigm, all deliveries to destinations within the United States are F.O.B origin, and all deliveries to destinations outside the U.S. are FCA Fluidigm’s facility (ICC Incoterms 2010). Unless specific shipping instructions have been agreed to in writing between Fluidigm and Olink, Fluidigm will ship in accordance with its standard practices and in compliance with all Applicable Laws. For multiple unit and/or multiple Product orders, Fluidigm may make delivery in installments, and each installment shall be deemed to be a separate sale. Fluidigm may issue a separate invoice for each installment, which invoice shall be paid without regard to prior or subsequent installments. Olink shall inspect all shipments promptly upon receipt and in the event of any shortage, visible damage or discrepancy in or to a shipment of any Product, Olink shall report the same to Fluidigm within five (5) business days after receipt thereof by Olink with sufficient detail with respect to the shortage, visible damage or discrepancy. Any Products not rejected by Olink within such five (5) business-day period shall be deemed to have been accepted by Olink. Without limiting Section 9.3, Fluidigm shall be entitled to repair or replace damaged, missing or nonconforming Products, and, subject to the warranty set forth in Section 9.3 and Fluidigm’s IP indemnification obligations under Section 12, such repair or replacement shall constitute Olink’s sole and exclusive remedies, and Fluidigm’s sole liability and obligation, for any damaged, missing or nonconforming Products.
​
	6.
	Purchase Orders, Price and Payments

​
6.1.Purchase Orders. After completion of all development activities contemplated under this Agreement or as otherwise agreed to by the Parties in writing, Olink may in good faith and in conformance with the terms of the Agreement, issue purchase orders, for the Products under this Agreement, which Fluidigm shall accept at quantities no greater than those defined in the Forecast (as defined below). Upon acceptance of a purchase order, this Agreement and such accepted purchase order shall constitute a contract between Olink and Fluidigm. If there is a conflict of terms between the terms of this Agreement and any such accepted purchase order, the terms of this Agreement shall prevail.
​
6.2.Purchase Orders Specifics. Each purchase order from Olink to Fluidigm shall identify the name, part number, quantity, and current unit price of each Product based on terms of the Agreement. Additionally, each purchase order from Olink to Fluidigm shall include the following information:
​
6.2.1.Requested delivery date
6.2.2.Bill-to instructions
6.2.3.Ship-to instructions
6.2.4.Customer contact information at the location for delivery
6.2.5.Any Customer-specific or order-specific instructions, as applicable
6.2.6.Dock height
6.2.7.Shipping/receiving hours
6.2.8.Customer contact information at the location for delivery
6.2.9.Country specific power cable (if none provided, Fluidigm shall ship with standard US power cable).
​
6.3.Taxes. Each Party shall be responsible for the payment of its own tax liabilities arising from this Agreement’s transaction. All transfer documentary, sales, use, stamp, registration, value added, and other such taxes and fees (including any penalties and interest) incurred in connection with this Agreement shall be borne and paid by the respective Party when due.
​
6.4.Currency. All references to “Dollars” or “$” shall mean the legal currency of the United States. All payments to be made under this Agreement shall be made in Dollars, unless expressly specified to the contrary herein.
​
6.5.Fluidigm Product Pricing. [***]
​
6.6.Pricing Exceptions and Adjustments. [***]
​
​

8
​

​
6.6.1.Pricing Exceptions. [***]
​
6.6.2.Price Adjustments. [***]
​
6.7.Products for Olink Research and Development. [***]
​
6.8.Sustaining Costs.  [***]
​
6.8.1. Annual Maintenance Fee: [***]
​
6.9.Olink Product Pricing. Olink will set the price for its sale of the Products and Reagents to customers at its sole discretion and may offer the Products and Reagents in connection with other Olink services or Products for a single price.
​
6.10.Payment. Fluidigm shall invoice Olink for all Product sales, and any and all Services ordered in connection with such Product(s), upon shipment of the Product, or if a service plan is purchased separately from the purchase of a Product, on the applicable start date of such Service plan and such invoice shall cover Olink’s purchase price for the Product and/or related Services and any freight, insurance, taxes or other applicable costs initially paid or payable by Fluidigm to be ultimately borne by Olink, and Olink shall pay all such amounts. Except as otherwise agreed to by the Parties, all invoices shall be issued and payable in Dollars, and are due and payable thirty (30) days from date of receipt of invoice and shall be made by wire transfer according to the following instructions: [***]
​
6.11.Separate and Independent Transactions. Each delivery shall be considered a separate and independent transaction and payment therefor made accordingly. Amounts outstanding thirty (30) or more days from the date of invoice shall be subject to a service charge of one percent (1.0%) per month, or the maximum allowed by Applicable Law, if less.
​
6.12.NRE Payments.  [***]
​
6.12.1.NRE Payment Terms. [***]
​
6.12.2.NRE Refund. [***]
​
6.13.Discretionary Development Pricing. [***]
​
	7.
	Forecasts

​
7.1.Annual Forecast. [***]
​
7.2.Manufacturing Forecast. [***]
​
7.3.Annual True Up. Prior to completion of the fourth quarter of each year, Olink agrees to purchase and accept delivery of Products amounting to the difference between the Products previously purchased during the Annual Forecast period and the Annual Forecast amount.
​
7.4.Initial Forecast .Olink shall provide Fluidigm in good faith with an initial six (6) month binding forecast (the “Initial Forecast”) for the Products no later than six (6) months prior to the Instrument System Validation milestone for the applicable Product as mutually agreed to in Exhibit D. In the event the end of the Initial Forecast does not align with the November 1 due date for the Annual Forecast, Olink shall provide an interim binding forecast for any fiscal quarters remaining until such time as the next Annual Forecast.
​
7.5.Excess Quantities. If there is an order in any quarter for more than the applicable Forecast,
​

9
​

Fluidigm agrees to consider in good faith the manufacture and delivery of such additional quantities of Product, and if Fluidigm confirms such additional quantities in writing, Fluidigm shall manufacture any quantity of Products ordered by Olink in excess of the applicable quantities in the Forecast for such quarter, provided, however, that notwithstanding the foregoing, Olink shall not be permitted to terminate this Agreement pursuant to Section 17.3(i) and shall not be entitled to receive the In-Term Manufacturing License, Post-Term Manufacturing License or release of the Escrow Materials as a result of any failure to supply such additional quantities.
​
	8.
	Customer Support and Surveillance

​
8.1.Olink shall serve as the point of customer contact and source of all follow-up to inquiries and complaints for all Products and Services listed in Exhibits A and B that are purchased by Olink from Fluidigm in accordance with terms of the Agreement, including through resolution, documentation of the inquiry or complaint, and troubleshooting with requisite root cause investigation.
​
8.2.Fluidigm shall provide support for requests for services outside the terms of a purchased service plan, technical inquiries that Olink cannot answer, and complaints with evidence that implicates a Product design or production defect (quality issues) for all Products and Services listed in Exhibits A (Products) and B (Services) that are purchased from Fluidigm in accordance with terms of the Agreement.
​
8.3.Parties agree to exchange information about complaints and inquiries associated with Products covered by the Agreement on a quarterly basis, the minimally required frequency, to provide visibility to Product input from end-users that may warrant preventative or corrective action, or indicate opportunities for Product improvements.
​
8.4.The Parties agree to notify each other within ten (10) business days of all complaints associated with regulatory issues.
​
	9.
	Representations and Warranties

​
9.1.Mutual Representations and Warranties. [***]
​
9.2.Fluidigm Representations. [***]
​
9.3.Fluidigm Warranty. [***]
​
9.4.Transfer of Warranty. For avoidance of doubt, the Fluidigm limited warranty provided in Section 9.3, above, shall transfer and pass-through to any and all Olink customers (including for clarity, any third parties that receive the Product from Olink authorized distributors).
​
9.5.WARRANTY DISCLAIMER. [***]
​
	10.
	Change of the Products

​
10.1.Specifications may be amended from time to time by the mutual written agreement of the Parties hereto which shall set forth in detail any changes in design of the Products.
​
10.2.Specifications also may be revised by Fluidigm to incorporate development changes where such changes do not adversely affect the price, delivery, guaranteed performance of the Products, interchangeability or replace ability requirements under such Specification or make unusable or obsolete any Products previously delivered to Olink pursuant to this Agreement.
​
	11.
	Trademark Usage

​
11.1.Use of Company Names. Fluidigm may identify Olink in Fluidigm advertising and marketing

10
​

materials provided that such materials are approved in writing in advance by Olink, such approval not to be unreasonably withheld. Olink may identify Fluidigm as the developer, manufacturer, and supplier of the Products in Olink’s advertising and marketing materials, provided that such materials are approved in writing in advance by Fluidigm, such approval not to be unreasonably withheld.
​
	12.
	Intellectual Property Infringement [***]

​
12.1.IP Infringement Defense. [***]
​
12.2.IP Infringement Indemnification. [***]
​
12.3.Exclusions. [***]
​
12.4.Exclusive Remedy.  [***]
​
	13.
	Indemnities

​
13.1.Olink Indemnification. [***]
​
13.2.Fluidigm Indemnification. [***]
​
13.3.Indemnification. [***]
​
13.4.Exclusions. Olink will have no obligation under this Section 13 to the extent that Fluidigm is obligated under Section 13.2 to defend Olink against such third party claim. Fluidigm will reimburse Olink for costs or damages that result from any such actions in accordance with this Section 13.
​
	14.
	Force Majeure

​
No Party shall be deemed in default of this Agreement for any delay or failure to fulfill any obligation (other than a payment obligation) hereunder or thereunder so long as and to the extent to which any delay or failure in the fulfillment of such obligation is prevented, frustrated, hindered, or delayed as a consequence of circumstances of Force Majeure Event. In the event of any such excused delay, the time for performance of such obligations (other than a payment obligation) shall be extended for a period equal to the time lost by reason of the delay. A Party claiming the benefit of this provision shall, as soon as reasonably practicable after the occurrence of any such event, (a) provide written notice to the other Party of the nature and extent of any such Force Majeure condition; and (b) use commercially reasonable efforts to remove any such causes and resume performance under this Agreement and the ancillary agreements, as applicable, as soon as reasonably practicable. For the purposes hereof, a “Force Majeure” or “Force Majeure Event” shall mean the occurrence of an event which materially interferes with the ability of a Party to perform its obligations or duties hereunder which is not within the reasonable control of the Party affected or any of its affiliates, and which could not with the exercise of commercially reasonable efforts have been avoided, including, but not limited to, war, rebellion, earthquake, fire, accident, strike, riot, civil commotion, act of God, epidemics, pandemics, inability to obtain raw materials, delay or errors by shipping companies or change in any Applicable Law.
​
	15.
	Limitation of Liability  [***]

​
	16.
	Confidentiality

​
16.1.Confidential Information. During the Term, each Party may provide to the other Party Confidential Information. “Confidential Information” shall mean information marked or otherwise identified as confidential by the Party providing Confidential Information (“Disclosing Party”) and disclosed to the Party receiving Confidential Information (“Recipient”) in confidence including, but not limited to, Background IP, Know-How, Specifications, trade secrets, all information, knowledge or
​

11
​

data of an intellectual, technical, scientific, commercial, financial or industrial nature, either in written documentation, oral or visual information, whether by inspection of parts or equipment or otherwise. In addition, any information or material which by its nature and under the circumstances surrounding its disclosure is generally considered proprietary and confidential shall be deemed Confidential Information.
​
16.2.Recipient Obligations. During the Term and for a period of ten (10) years thereafter, the Recipient agrees to: (a) hold all Confidential Information in confidence and will not, directly or indirectly, publish, disseminate or otherwise disclose, deliver or make available to any third party any Confidential Information, except as expressly permitted in this Agreement; (b) use Confidential Information solely for the purposes set forth in this Agreement; (c) treat Confidential Information with the same degree of care it uses to protect its own confidential information, but in no event with less than a reasonable degree of care; and (d) reproduce Confidential Information solely as necessary to accomplish the purposes set forth in this Agreement. Recipient may disclose Confidential Information to its employees, consultants, and agents on a need-to-know basis, but only if: (i) those employees, consultants, and agents are bound by written obligations of confidentiality at least as restrictive as those in this Agreement; (ii) Recipient remains liable for the compliance of those employees, consultants, and agents; and (iii) such disclosures are required for the purposes set forth in this Agreement.
​
16.3.Exceptions. The Recipient shall have no obligation of confidentiality and non-use with purposes set forth in this Agreement to any portion of Confidential Information that the Recipient can establish by competent evidence:
​
16.3.1.is, or later becomes, generally available to the public or trade by use, publication or the like, through no fault or omission of the Recipient;
​
16.3.2.is obtained from a third party who had the legal right to disclose the same to the Recipient;
​
16.3.3.is already in Recipient’s possession other than by previous disclosure by the Disclosing Party; or
​
16.3.4.independently developed at any time by the Recipient, its employees or agents with no knowledge of or access to the Confidential Information.
​
16.4.Compulsory Disclosure. In the event that the Recipient is required to disclose Confidential Information pursuant to law or government regulation, duly authorized subpoena or court order, whereupon the Recipient shall, unless prohibited by Applicable Law, provide notice, including a copy of such subpoena or court order, to Disclosing Party prior to such disclosure, and shall disclose only the minimum Confidential Information required, and any such disclosure will be pursuant to the highest level of confidentiality available under the applicable protective order or other governing agreement, order, or regulation.
​
	17.
	Term and Termination

​
17.1.Term. This Agreement will commence upon the Effective Date and continue for seven (7) years (“Initial Term”), unless earlier terminated in accordance with the provisions of this Agreement. This Agreement will automatically renew for additional successive twenty-four (24) month terms unless either Party provides written notice to the other Party of its intent not to renew at least one hundred and eighty (180) days before the end of the then-current term.
​
17.2.Termination for Uncured Breach. If either Party fails to perform any of its material obligations under this Agreement, including payment in accordance with Section 6 the other Party may terminate this Agreement by giving ninety (90) days’ prior written notice, provided that the matters set forth in such notice are not cured to the other party’s reasonable satisfaction within the ninety (90) day
​

12
​

period (the “Cure Period”).
​
17.3.Termination by Olink. Olink may terminate this Agreement upon ninety (90) days prior written notice based on (i) Fluidigm’s failure to supply the Products in accordance with purchase orders that meet requirements of the Agreement and align with the Annual Forecast; (ii) if Fluidigm undergoes a Change of Control event and, except in the event of a merger where Fluidigm is the surviving entity, the Agreement is not specifically assumed as part of such Change of Control; or (iii) a single Product SKU fails to meet agreed-to quality Specifications on a recurring basis over two (2) consecutive calendar quarters and for which such deficiency is not cured or if Fluidigm does not provide a plan for correcting such deficiency during the Cure Period.
​
17.4.Termination by Fluidigm. Fluidigm may terminate this Agreement upon thirty (30) days written notice, based on (i) Olink’s failure to pay any amounts due hereunder; and (ii) Olink discontinues the commercial sale of any of the Products within Field of Use; and (iii) Olink’s failure to meet its purchase commitment for the Products set forth in the Initial, Annual and Manufacturing Forecasts as defined in Section 7.
​
17.5.Termination for Bankruptcy or Insolvency. This Agreement may be terminated immediately by either Party upon occurrence of any of the following events: (i) insolvency of the other Party; (ii) filing by or against the other Party of voluntary or involuntary petition in bankruptcy or for any similar relief; or (iii) the execution of an assignment by the other Party for the benefit of creditors or appointment of a receiver of the other Party for any reason.
​
17.6.No Liability for Termination. Except as expressly required by law, in the event of termination of this Agreement by either Party in accordance with any of the provisions of this Agreement, neither Party will be liable to the other, because of such termination, for compensation, reimbursement, or damages on account of the loss of prospective profits or anticipated sales or on account of expenditures, inventory, investments, leases, or commitments in connection with the business or goodwill of Fluidigm or Olink. Termination will not, however, relieve either Party of obligations incurred prior to the Effective Date of the termination.
​
17.7.Effect of Termination. Upon termination, each Party shall immediately return, or certify in writing destruction thereof, all Background IP and Confidential Information to the respective owner(s).
​
17.8.Survival. Except as may be set forth otherwise, all rights and obligations of the Parties set forth herein that expressly or by their nature survive the expiration or termination of this Agreement (including without limitation all rights under outstanding Purchase Orders) shall continue in full force and effect subsequent to and notwithstanding the expiration or termination of this Agreement until they are satisfied or by their nature expire and shall bind the Parties and their legal representatives, successors, and permitted assigns. The termination or expiration of this Agreement will not relieve Olink of the obligation to pay any fees that are due to Fluidigm under this Agreement.
​
	18.
	Supply Continuity

​
18.1.Shortage of Products
​
18.1.1.   Fluidigm understands and acknowledges that Fluidigm is solely responsible for managing and maintaining its relationships with third party suppliers that it uses to obtain components necessary to manufacture the Product, and that any disruption in the manufacture of the Product or a component thereof that is due to any such third party supplier shall be Fluidigm’s responsibility, including with regard to any impact on the timely delivery to Olink of Product ordered under this Agreement.
​
18.1.2.  If Fluidigm experiences a shortage of Product due to (a) Force Majeure or (b) supply failures by a third party component supplier and is unable to supply the full quantity of Product ordered pursuant to this Agreement that quantity which bears the same proportion to the total quantity of
​

13
​

available Product as the quantity of Product supplied by Olink in the six (6) months preceding the supply shortage bears to all orders for Product received by Fluidigm (including amounts of instruments manufactured by Fluidigm for its own account) during that same six (6)-month period. Fluidigm shall use commercially reasonable efforts to work with Olink to meet Olink’s additional supply needs for Product during the period that any Product shortage conditions exist.
​
18.2.Cooperation. In the event Fluidigm determines that shortage conditions will occur, or in the event of a Force Majeure or supplier delay that gives rise to shortage conditions, Fluidigm will promptly notify Olink of such conditions, and the Parties shall discuss in good faith appropriate mechanisms to address such shortage conditions.
​
18.3.Supply Continuity During Term of this Agreement. [***]
​
18.4.Supply Continuity Upon Termination of this Agreement. [***]
​
	19.
	Technology Escrow and Technology Transfer [***]

​
	20.
	Notices and Other Communications

​
20.1.Except as either party may herein after notifying the other party in writing with respect to itself, the addresses of the parties for the purpose of this Agreement shall be:
​
Olink Proteomics AB
Address:Uppsala Science Park, Uppsala, SE75183, Sweden
ATTN: CFO
Email address: oskar.hjelm@olink.com
With a Copy to: linda.ramirez@olink.com
​
Fluidigm Corporation
Telephone No.: (650) 266-6000
Address:Two Tower Place, Suite 2100
South San Francisco, CA 94080
ATTN: General Counsel
Email address: legal@fluidigm.com
​
20.2.All orders, policies, reports, payments and communications pursuant hereto are to be delivered to the intended receiving party by hand or by facsimile, or by airmail, postage prepaid, to the address provided in this Section 20, and shall be deemed delivered when handed or mailed to the intended receiving party.
​
	21.
	Severability

​
This Agreement is intended to be valid and effective throughout the world and, to the extent permissible under Applicable Law, shall be construed in a manner to avoid violation of or invalidity under any Applicable Law. Should any provision hereof nevertheless be or become invalid, illegal or unenforceable under any Applicable Law, the other provisions hereof shall not be affected, and to the extend permissible under Applicable Law, any such invalid, illegal or unenforceable provision shall be deemed amended lawfully to conform to the intent of the Parties.
​
	22.
	Governing Law

​
The validity, construction, and performance of this Agreement shall be governed by and interpreted in accordance with the laws of the California.
​
	23.
	Non-Assignability

​

14
​

Neither Party shall assign this Agreement nor any rights hereunder to any third parties without the prior written consent of the other Party which shall not be unreasonably withheld, except that each Party may assign this Agreement and the rights, obligations, and interests of such Party, (i) in whole or in part, to any of its Affiliates; or (ii) in whole, but not in part, to any purchaser of all of its assets or all of its assets to which this Agreement relates. A Party assigning this Agreement, or any of its rights under this Agreement to a third party shall provide notice of such assignment to the non-assigning Party within ten (10) business days of the assignment. Subject to the preceding sentence, this Agreement shall apply to, be binding in all respects upon and inure to the benefit of the successors and permitted assigns of the Parties to this Agreement.
​
	24.
	Foreign Corrupt Practices Act

​
In conformity with the United States Foreign Corrupt Practices Act (the “FCPA”) and with Fluidigm’s corporate policies regarding foreign business practices as disclosed to Olink, Olink and, to Olink’s knowledge, its employees and agents, will not directly or indirectly make and offer payment, promise to pay, or authorize payment, or offer a gift, promise to give, or authorize the giving of anything of value for the purpose of influencing an act or decision of an official of any government (including a decision not to act) or inducing such a person to use his influence to affect any such governmental act or decision in order to assist Fluidigm in obtaining, retaining, or directing any such business, in violation of the FCPA.
​
	25.
	Entire Agreement and Modification

​
25.1.Entire Agreement. This Agreement constitutes the entire understanding of the Parties relating to the subject hereof and supersedes all other previous agreements and understandings, whether written or oral.
​
25.2.Amendments. This Agreement may be amended or modified only in writing signed by the duly authorized representatives of the respective Parties.
​
25.3.Counterparts. This Agreement may be executed by the Parties in any number of counterparts, each of which when so executed and delivered shall be deemed to be an original, but all of which shall constitute one and the same agreement. The Parties agree that this Agreement, if affixed with a digital signature or signed and submitted by facsimile, or by e- mail as a scanned document, will be deemed an original signed Agreement binding on the Parties.
​
25.4.Headings. Paragraph headings are for convenience only and shall not be used in the interpretation of this Agreement or construed as a limitation of the scope of the particular section to which they refer.
​
IN WITNESS WHEREOF, each Party hereto has caused this Agreement to be executed in duplicate in English, as of the Effective Date above written, by its duly authorized representative.
​
​
	​

	​

	​

	​

	​

	Olink Proteomics AB
	​
	Fluidigm Corporation

	​
	​
	​

	By: 
	/s/ Jon Heimer
	​
	By: 
	/s/ Christopher Linthwaite

	Name:
	Jon Heimer
	​
	Name:
	S. Christopher Linthwaite

	Title: 
	CEO
	​
	Title: 
	President and CEO

	Date: 
	3/31/2020
	​
	Date: 
	3/31/2020

​

15
​

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]